Hospital Psychiatry - Articles - Page 8

Fact Sheet

Stimulant Use Disorders Treatment

January 1, 2025

Victoria Hendrick, MD and Daniel Carlat, MD

Dr. Hendrick and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Stimulant use disorders are all too common among patients in psychiatric units.

Fact Sheet

Buprenorphine Microinduction

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The standard method of starting a patient on buprenorphine involves having the patient stop all opioids hours to days before the induction.

Fact Sheet

Buprenorphine Monotherapy (Subutex, others)

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Buprenorphine (Subutex, available now only as generic) is the active ingredient in Suboxone (buprenorphine/naloxone) and is responsible for the effectiveness of the combination medication in opioid use disorder (OUD).

Fact Sheet

Buprenorphine Extended-Release Injection Monotherapy (Brixadi, Sublocade)

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Extended-release injectable formulations of buprenorphine allow patients to receive doses weekly, monthly, or every eight weeks for patients maintained on a low dose—which improves medication adherence.

Clinical Guidance

Medication Interactions

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Opioid use disorder (OUD) is highly comorbid with medical illness and other psychiatric conditions.

Clinical Guidance

Neonatal Opioid Withdrawal Syndrome: Recognition and Management

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Neonatal opioid withdrawal syndrome (NOWS), sometimes used interchangeably with the term neonatal abstinence syndrome (NAS), results from prenatal opioid exposure.

Clinical Guidance

Managing Opioid Use Disorder in Pregnant People

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Rates of opioid use disorder (OUD) and overdose deaths during pregnancy have skyrocketed in recent years.

Clinical Guidance

Levels of Care for Opioid Use Disorder Services

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

This fact sheet offers insights into various services for opioid use disorder (OUD), highlighting their definitions, typical durations, and referral considerations to optimize patient care.

Clinical Guidance

How to Use Sublocade and Brixadi

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Sublocade and Brixadi are long-acting forms of injectable buprenorphine given once every four or eight weeks for Sublocade and weekly or monthly for Brixadi.

Clinical Guidance

Pain Management for Patients With Opioid Use Disorder

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Pain and opioid use disorder (OUD) are tightly intertwined and highly comorbid.

Hospital Psychiatry
RSS

Stimulant Use Disorders Treatment

Buprenorphine Microinduction

Buprenorphine Monotherapy (Subutex, others)

Buprenorphine Extended-Release Injection Monotherapy (Brixadi, Sublocade)

Medication Interactions

Neonatal Opioid Withdrawal Syndrome: Recognition and Management

Managing Opioid Use Disorder in Pregnant People

Levels of Care for Opioid Use Disorder Services

How to Use Sublocade and Brixadi

Pain Management for Patients With Opioid Use Disorder

Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

Gender Affirming Care in Exile: The Lawsuits

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

About

Shop Online

Newsletters

Contact

Follow Us

Hospital Psychiatry RSS

About

Shop Online

Newsletters

Contact

Follow Us

Hospital Psychiatry
RSS